Hologen, Sysmex Form AI Venture To Analyse Blood Test Data

KUALA LUMPUR, Nov 10 (Bernama) -- Hologen, a frontier artificial intelligence (AI) company, and Sysmex Corporation, a Japanese haematology company, have formed Saibogen, a joint venture that will use generative AI to draw more information from routine blood tests.

Saibogen will apply Hologen’s Large Medicine Models, AI models that learn the biology behind real-world healthcare data, to data from Sysmex haematology analysers, which run about three billion blood count tests a year.

“Every routine blood count measures tens of thousands of cells with remarkable precision, and much of that information goes unused,” said Saibogen chief executive officer (CEO), Leila Luheshi.

The joint venture aims to give researchers and clinicians new insights without requiring new instruments, reagents or samples, according to a statement.

“Blood is one of the richest sources of biological information we have. Our Large Medicine Models are built to learn that biology from real-world data,” said Hologen CEO, Roland Tegeder.

Meanwhile, Sysmex president, Iwane Matsui said the venture would combine Sysmex’s haematology expertise and global business platform with Hologen’s AI technologies to unlock new value from routine blood testing data.

Saibogen’s products will be delivered as software exclusively through Sysmex’s haematology analysers, with its first offerings for research use only.

-- BERNAMA